Work

Abstract OT-13-10: Global Phase 3 Study of Adagloxad Simolenin (OBI-822) and OBI-821 Versus Placebo Treatment for High Risk Early Stage Triple Negative Breast Cancer Patients (TNBC) Following Neoadjuvant or Adjuvant Chemotherapy

Year: 2021

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.sabcs20-ot-13-10

Authors: Hope Rugo, Louis W.C. Chow, Javier Cortes, Peter A. Fasching, Xu-Bing He, Pei Hsu, Chiun-Sheng Huang, Sung-Bae Kim, Yen-Shen Lu, Michelle Melisko, Rita Nanda, Tillman E Pearce, Priyanka Sharma, Richard Schwab

Institutions: University of California, San Francisco, Unimed Medical Institute, Hospital Universitario Ramón y Cajal, Friedrich-Alexander-Universität Erlangen-Nürnberg, Chinese Academy of Medical Sciences & Peking Union Medical College, National Taiwan University Hospital, University of Chicago, University of Chicago Medical Center, University of Kansas Medical Center, University of California San Diego

Language: English

Topic: Breast Cancer Treatment Studies

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3133310135

Cites:

Cited by: 1

Related to: 10